Approval for Diabetes and Weight Management Over the past decade, three GLP-1/GIP receptor agonists liraglutide, semaglutide, and tirzepatide initially approved by the FDA for adults with type 2 diabetes, have also gained FDA approval for chronic weight management in people without diabetes, provided they meet specific criteria: a BMI of 30, or 27 with at least one weight-related condition such as hypertension, dyslipidemia, or type 2 diabetes
This will be a central focus of the FDA review
This effect helps prevent post-meal spikes in blood sugar, which are often a challenge for individuals with diabetes
Because oral options sit directly within the stomach to be absorbed, some patients report a higher frequency of upper gastrointestinal symptoms, including acid reflux, indigestion, and localised stomach discomfort during the morning fasting window
These advances do not change the fundamental classification
We are a global strategy consulting firm that assists business leaders in gaining a competitive edge and accelerating growth